Navigation Links
Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA
Date:3/15/2011

REDWOOD CITY, Calif., March 15, 2011 – Ingenuity® Systems, a leading provider of information and analytics solutions for life science researchers, today announced new features to support RNA-Sequencing workflows and microRNA research in IPA®. Processed RNA-Seq datasets can now be uploaded directly into IPA and analyzed in the context of pathways and diseases for a rich biological interpretation of the data. This helps researchers quickly and accurately focus on the most important information within their large RNA-Seq datasets quickening the pace of research. IPA also now includes a unique new microRNA Target Filter, making IPA the only commercially available tool that allows researchers to examine both predicted and experimentally demonstrated microRNA-mRNA pairings, prioritize targets based on relevant biological context, and visualize the molecular interactions of those target relationships and related biological impacts.

"The new microRNA Target Filter plus the additional microRNA content is an ideal combination to help prioritize miRNA target interactions," stated Aaron Sarver Ph.D., University of Minnesota. "IPA users can quickly filter those interactions based on relevant biology, and then visualize the biological effects of target interactions. IPA makes it much simpler to find interesting insights, and allows me to systematically utilize the miRNA literature to generate novel testable hypotheses."

"Whether our customers are working with 'omics or next-generation sequencing platforms, there is a fundamental gap between the output of data and the ability to analyze and interpret the results in a meaningful biological way," stated Doug Bassett, Ph.D., CSO and CTO, Ingenuity Systems.  "IPA 9.0 narrows this gap with support for new platforms, new analytics, and complementary new content all designed to support key needs of our customers, such as biological interpretation of microRNA and NGS datasets.  IPA has become the industry standard for delivering powerful biological insights from large scale data, and we are pleased to be able to offer exciting new capabilities to researchers in these rapidly growing research areas. Regardless of platform, it's clear that examining genes in the context of known molecular relationships, biological processes, and disease relationships, provides a faster and more reliable way to identify key insights from complex data."

The latest release of IPA includes significant feature enhancements designed to help researchers get maximum value from data generated by NGS, microarray, and 'omics experiments:

New first-of-a-kind microRNA Target Filter capability and microRNA content:  Get insight into the biological effects of microRNAs using both experimentally demonstrated and predicted microRNA-mRNA relationships.

  • Identify mRNA targets for microRNAs using newly added predicted microRNA–mRNA binding relationships from TargetScan, in addition to information on experimentally validated relationships from TarBase.
  • Reduce number of steps to confidently identify targets by examining microRNA-mRNA pairings, exploring the related biological context of these relationships, and filtering mRNA targets based on relevant biological characteristics, all within a single tool.
  • Easily prioritize mRNA target interactions based on confidence levels of interaction predictions, source, role or presence in species, diseases, tissues, pathways, cell lines, molecular types, and more.
  • Elucidate the mechanism of action of microRNAs.
  • Leverage microRNA and mRNA data in combination with other types of datasets for an integrated biological analysis.

Expanded RNA-Seq workflow: Directly upload processed RNA-Seq datasets into IPA to analyze and understand RNA-Seq data in the context of known biology to get a comprehensive view of the experimental system.

  • Quickly move beyond statistical analysis of high-throughput RNA-Seq data to understand the biological implications of your data, so you can accurately identify novel disease mechanisms, prioritize drug targets, generate hypotheses, and more.
  • Seamlessly move from data processing tools to biological interpretation in IPA by directly uploading RefSeq, Ensembl, and UCSC IDs.

Enhanced user interface: IPA's new quick-start and usability enhancements support a more intuitive user interaction and streamlined access to a variety of important workflows. Researchers can upload and analyze their data in one simple step, more quickly search for genes or pathways, and more easily visualize connections among genes.  

For more information about IPA, please visit: http://www.ingenuity.com/products/pathways_analysis.html or sign up for a free trial at http://www.ingenuity.com/products/IPA/Free-Trial-Software.html

About Ingenuity® Systems

Ingenuity Systems is a leading provider of information solutions and custom services for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. For more information visit: www.ingenuity.com


'/>"/>
SOURCE Ingenuity Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ingenuity Systems and TransMed Systems Integrate Software to Support Personalized Medicine Research
2. Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter
3. ShangPharma Announces Fourth Quarter and Fiscal Year 2010 Results
4. New Aid for AIDS - ICAP Ocean Tomo Announces Auction of a Keystone Patent for Cell Therapy Use of Modified Red Blood Cells for Treating Viral Diseases
5. American Scientific Resources Announces New Distributor Syner-Med Placing Kidz-Med VeraTemp in the United Kingdom and Ireland
6. OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent
7. Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
8. China-Biotics, Inc. Announces the Results of the 2010 Annual Meeting of Stockholders
9. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
10. Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012
11. Nephros Announces Completion of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
(Date:3/27/2017)... 27, 2017 Summary This ... Eli Lilly and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced ... efficacy studies. The company is harnessing the power of ... A, in an effort to find a better treatment ... 4 weeks of treatment in transgenic mice, the lead ... a full toxicology report of various organs. Cytotoxic T-cells ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved ... procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive list ...
(Date:3/28/2017)... ... 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of all ... lot to offer to the discussion of dealing with excess skin oil. “Oily skin is ... home remedies that can help remove the oily shine while keeping the skin fresh and ...
(Date:3/27/2017)... Aurora, CO (PRWEB) , ... March 27, 2017 , ... ... Dr. Mark Braasch for leading sleep apnea treatment, with or without a referral. Sleep ... the condition, which can include daytime sleepiness, morning headaches and chronic snoring. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
Breaking Medicine News(10 mins):